

Contents

List of contributors	xv
Preface	xxi
1. Biomarkers in bipolar disorder: an overview	1
<i>Estela Salagre and Eduard Vieta</i>	
1.1 Introduction	1
1.2 Biomarker definition and rationale for biomarkers in bipolar disorder	2
1.3 Biomarker categories and potential uses in bipolar disorder	5
1.3.1 Risk biomarkers	5
1.3.2 Diagnosis/trait biomarkers	6
1.3.3 State or acuity biomarkers	7
1.3.4 Stage biomarkers	7
1.3.5 Prognostic biomarker	8
1.3.6 Treatment response biomarker	8
1.4 Biomarkers in bipolar disorder: current limitations	9
1.5 Future directions in the field of biomarkers in bipolar disorder	11
1.6 Conclusion	12
References	12
2. Neural biomarkers of suicidal behavior: from cognition and circuits to cells (and back)	19
<i>Fabrice Jollant and Naguib Mechawar</i>	
2.1 Neurocognitive studies of suicidal behavior	20
2.1.1 Risky decision-making	20
2.1.2 Deficient social cognition	21
2.1.3 Other cognitive processes: memory, attention, and cognitive inhibition	23
2.1.4 Resting state neuroimaging studies	24
2.1.5 Pharmacological neuroimaging studies	25
2.1.6 Structural neuroimaging studies	25
2.1.7 Using neuroimaging studies for classification	26
2.1.8 A tentative neuroanatomical summary of suicidal acts	26

2.2	Postmortem brain research: exploring the cellular and molecular roots of suicide	27
2.2.1	Evidence of activated microglia/macrophages	28
2.2.2	Molecular evidence of increased inflammation in depression and suicide	29
2.2.3	Inflammation and cognition	30
2.2.4	Bipolar disorder	30
	Acknowledgment	30
	References	31
3.	Metabolomics of bipolar disorder	39
	<i>Camila Nayane de Carvalho Lima and Gabriel R. Fries</i>	
3.1	Metabolomics in psychiatric disorders	39
3.2	Biomarkers in bipolar disorder	41
3.3	Metabolomics in bipolar disorder	42
3.3.1	Brain tissue and cerebrospinal fluid metabolomics analysis	42
3.3.2	Blood and urine metabolomic analyses	44
3.3.3	Pharmacometabolomics of bipolar disorder	49
3.4	Future directions of metabolomics as a tool for biomarker discovery and clinical implications	51
	References	53
4.	Behavioral models of bipolar disorder	63
	<i>Roger B. Varela, Gustavo C. Dal-Pont, Joao Quevedo and Samira S. Valvassori</i>	
4.1	Background	63
4.2	Animal models of mania	65
4.2.1	Environmental models of mania	65
4.2.2	Pharmacological models of mania	66
4.2.3	Surgical model of mania	67
4.2.4	Genetic models of mania	68
4.3	Mania-like behavior assessment in animals	70
4.3.1	Open-field test	70
4.3.2	Delayed discounting task	71
4.3.3	Resident–intruder test	71
4.3.4	Sexual behavior test	72
4.4	Animal models of depression	72
4.4.1	Environmental models of depression	72
4.4.2	Pharmacological models of depression	74
4.4.3	Surgical model of depression	74
4.4.4	Genetic models of depression	75
4.5	Depressive-like behavior assessment in animals	76
4.5.1	Forced swimming test	76
4.5.2	Tail suspension test	76

4.5.3	Sweet food consumption test	76
4.5.4	Splash test	77
4.5.5	Effort-Related Choice Task	77
4.6	Conclusions and future directions	77
	References	79
5.	Structural neuroimaging markers in bipolar disorder	81
	<i>Mehmet Akif Camkurt, Benson Mwangi, Marsal Sanches and Jair C. Soares</i>	
5.1	Introduction	81
5.2	Biomarker concepts and neuroimaging markers in psychiatry	82
5.3	Structural neuroimaging in psychiatry	82
5.3.1	Overview of existing literature	83
5.3.2	Diffusion tensor imaging	83
5.4	Neuroimaging as a tool to improve the diagnostic accuracy of bipolar disorder	84
5.4.1	Distinguishing bipolar disorder from schizophrenia	84
5.4.2	Distinguishing bipolar disorder from unipolar depression	85
5.5	Neuroimaging markers in high-risk populations	87
5.6	Summary and conclusions	88
	References	89
6.	Magnetic resonance spectroscopy in bipolar disorder	95
	<i>Courtney M. Vecera, Audrey C. Chong, Ana C. Ruiz, Carola Rong, Gregory Jones, Rodrigo Machado-Vieira and Jair C. Soares</i>	
6.1	Background	95
6.2	Proton magnetic resonance spectroscopy	95
6.3	Metabolite abnormalities in bipolar disorder	96
6.3.1	Glutamatergic hyperactivity	96
6.3.2	Mitochondrial dysfunction and neuronal alterations	98
6.3.3	Intracellular signaling abnormalities	102
6.4	Brain regions involved in cognitive and affective regulation	104
6.5	Conclusion and future directions	106
	References	107
	Further reading	112
7.	Precision psychiatry in bipolar disorder	115
	<i>Bárbara Tietbohl-Santos, Thyago Antonelli Salgado, Thiago Henrique Roza and Ives Cavalcante Passos</i>	
7.1	Introduction	115
7.2	Diagnosis and differential diagnosis	116
7.3	Prognosis prediction	118
7.4	Suicidality prediction	119
7.5	Treatment selection	120
7.6	Supervised and unsupervised learning	121

7.7 Conclusion	121
References	122
8. Genome-wide association study biomarkers in bipolar disorder	125
<i>Gustavo C. Medeiros and Fernando S. Goes</i>	
8.1 Introduction	125
8.2 Generic epidemiology: heritability and family studies	126
8.3 Genome-wide association studies	126
8.4 Recent results of genome-wide association studies in bipolar disorder	127
8.5 Fine mapping: from loci to genes	129
8.6 Common variant heritability and coheritability	130
8.7 Polygenic risk scores	131
8.8 Missing heritability	133
8.9 Genome-wide association studies and treatment of bipolar disorder (pharmacogenetics)	133
8.10 Challenges and opportunities for the next era of genome-wide association studies in bipolar disorder	134
8.11 Conclusions	135
References	135
9. Mitochondrial dysfunction in bipolar disorder	141
<i>Tadafumi Kato</i>	
9.1 Introduction	141
9.2 Proposal of mitochondrial hypothesis	141
9.3 Cellular models	142
9.4 Cerebrospinal fluid	144
9.5 Genetics	144
9.6 Postmortem brains	146
9.7 Animal models	147
9.8 Drug discovery research	149
9.9 iPS cell model	149
9.10 Molecular and cellular pathogenesis in the paraventricular thalamic nucleus (PVT) and action mechanisms of antibipolar drugs	150
9.11 Neural circuits around the paraventricular thalamic nucleus (PVT)	151
9.12 Conclusion	151
Acknowledgments	152
References	152
10. Mechanisms of aging in bipolar disorder	157
<i>Breno Satler Diniz</i>	
10.1 Introduction	157

10.2	Cellular senescence and telomere attrition in bipolar disorder	157
10.3	Epigenetic alterations, DNA damage, and genomic instability	158
10.4	Mitochondria dysfunction	159
10.5	Altered intercellular communication	160
10.6	Concluding remarks	161
	References	162
11.	Neuroprogression in bipolar disorder	167
	<i>Massimo Tusconi and Gabriel R. Fries</i>	
11.1	Introduction	167
11.1.1	Bipolar disorder	167
11.1.2	Evidence of (neuro)progression in bipolar disorder	168
11.2	Clinical evidence of neuroprogression	169
11.2.1	Clinical features	169
11.2.2	Neurocognitive changes	170
11.2.3	Functioning	171
11.3	Biological basis of neuroprogression	171
11.3.1	Neuroanatomical changes	171
11.3.2	The dualism of neurodegeneration versus neuroplasticity	173
11.3.3	Molecular changes associated with the progression of illness	175
11.3.4	Insulin signaling and hypothalamic–pituitary–adrenal axis dysregulation	176
11.4	Future perspectives of the field	177
11.5	Conclusions	179
	References	179
12.	Neuroimmune pathways in bipolar disorder	191
	<i>Izabela G. Barbosa, Moises E. Bauer and Antonio L. Teixeira</i>	
12.1	On the search for the “black bile”	191
12.2	Immune system: an overview	192
12.3	Evidence of immune dysfunction in bipolar disorder	194
12.3.1	Genetic evidence	194
12.3.2	Clinical evidence	195
12.3.3	Inflammatory markers in the central nervous system and microglial activation	196
12.3.4	Immune cells: total count, phenotype, and function	197
12.3.5	Circulating levels of immune markers	199
12.4	Immune (cerebrospinal fluid and blood) markers of diagnosis in other psychiatric conditions (major depressive disorder and schizophrenia)	200

12.5	Integrating immune dysfunction with the pathogenesis, physiopathology, and prognosis of bipolar disorder	201
12.6	Immune-based strategies for bipolar disorder	204
12.7	Immune markers as predictors of treatment mood response	205
12.8	Conclusion	205
	References	206
13.	Glutamate-based preclinical and clinical dysfunction and treatment in bipolar disorder	215
	<i>Amanda Decker, Brandon Bacalzo and Mark J. Niciu</i>	
13.1	Preclinical	215
13.2	Clinical	219
13.2.1	Magnetic resonance spectroscopy	219
13.2.2	Electroencephalography	223
13.2.3	Positron emission tomography	226
13.2.4	Glutamate receptor-based biomarkers	227
13.3	Treatment	233
13.3.1	Lamotrigine	233
13.3.2	Riluzole	236
13.3.3	Ketamine	237
13.4	Conclusion	241
	References	241
14.	Neurocognitive endophenotypes in bipolar disorders	253
	<i>Alexandre Paim Diaz, Joao Quevedo, Marsal Sanches and Jair C. Soares</i>	
14.1	Cognitive dysfunctions in bipolar disorders	253
14.2	Impact of cognitive dysfunctions in bipolar disorders	254
14.3	Concept of endophenotypes	255
14.4	Neurocognitive endophenotypes in bipolar disorders	257
14.4.1	Affective cognition	260
14.4.2	Limitations of neurocognitive endophenotypes in bipolar disorders	261
14.5	Conclusion	263
	References	263
15.	DNA methylation in bipolar disorder	267
	<i>Bradley H. Howlett, Marissa A. Kassa and Kyle J. Burghardt</i>	
15.1	Introduction	267
15.1.1	DNA methylation	267
15.1.2	Measurement of DNA methylation	268
15.1.3	Sample source for DNA methylation analysis	269
15.1.4	Role of DNA methylation in bipolar disorder	269
15.2	DNA methylation and bipolar disorder diagnosis	270

15.2.1	Global methylation studies of bipolar disorder	270
15.2.2	Whole-genome analyses	270
15.2.3	Gene-specific analyses	276
15.3	DNA methylation and treatment response in bipolar disorder	278
15.3.1	Global methylation	278
15.3.2	Whole-genome analyses	281
15.3.3	Gene-specific studies	281
15.4	DNA methylation and animal and preclinical model studies of bipolar disorder	283
15.5	Summary	286
	References	286
16.	Biomarkers of lithium efficacy in bipolar disorders	293
	<i>Janusz K. Rybakowski</i>	
16.1	Lithium's efficacy	293
16.2	Biomarkers of lithium prophylaxis efficacy	294
16.3	Biomarkers for lithium efficacy in acute mood episodes	299
16.4	Conclusions	306
	References	306
17.	Neuroendocrine and stress pathways in bipolar disorders	313
	<i>Mario F. Juruena, Anthony J. Cleare and Allan H. Young</i>	
17.1	Introduction	313
17.2	The hypothalamus–pituitary–adrenal axis	314
17.3	Steroid hormones	316
17.4	Mineralocorticoid receptors and glucocorticoid receptors	316
17.5	Neuroendocrine function test	320
17.6	Impact of stress on bipolar disorders	324
17.7	Conclusion	325
	References	326
18.	Intracellular signaling cascades in bipolar disorder	331
	<i>Courtney M. Vecera, Gregory Jones, Audrey C. Chong, Ana C. Ruiz, Carola Rong, Jair C. Soares and Rodrigo Machado-Vieira</i>	
18.1	Introduction	331
18.2	Calcium signaling	331
18.3	Diacylglycerol and protein kinase C pathways	333
18.4	GSK3- β and Wnt pathways	335
18.5	Brain-derived neurotrophic factor	337
18.6	Mitochondrial dysfunction	338
18.7	Conclusion	339
	References	339

19. Circadian biomarkers of bipolar disorder	349
<i>Kathleen Ries Merikangas and Ananya Swaminathan</i>	
19.1 Biomarkers of bipolar disorder	349
19.1.1 Sleep characteristics	349
19.1.2 Light sensitivity	351
19.2 Objectively measured sleep, activity, and circadian rhythms	351
19.2.1 Sleep	352
19.2.2 Motor activity	352
19.2.3 Circadian rhythms	353
19.3 Endophenotypes for bipolar disorder	354
19.4 Summary, challenges, and opportunities for future research	355
Acknowledgments	356
References	356
20. DNA damage and repair mechanisms in bipolar disorder	361
<i>Ayşegül Özerdem and Deniz Ceylan</i>	
20.1 Introduction	361
20.2 Oxidative stress and its relevance to bipolar disorder	362
20.3 DNA damage and repair mechanisms	363
20.4 DNA damage markers in bipolar disorder	364
20.5 Quantification of 8-oxo-dG in bipolar disorder	366
20.6 DNA damage and affective states of bipolar disorder	367
20.7 DNA repair markers in bipolar disorder	369
20.8 Future directions	372
20.8.1 Mitochondrial DNA damage and repair and bipolar disorder	372
20.8.2 Cancer research and bipolar disorder	373
References	374
21. Microbiome and bipolar disorder	385
<i>Estela Salagre, Jose Alberto Moreno and Iria Grande</i>	
21.1 The microbiota-gut-brain axis: a new approach in bipolar disorder biomarkers	385
21.1.1 Introduction	385
21.2 The microbiota-gut-brain axis	386
21.2.1 Consequences of microbiota-gut-brain axis alteration	387
21.2.2 Microbiota-gut-brain axis and mental health	388
21.2.3 Available tools to explore the microbiota-gut-brain axis	389
21.3 Microbiota-gut-brain axis and bipolar disorder: gut microbiota as a potential biomarker for bipolar disorder	391
21.3.1 Gut microbiota as diagnostic biomarker for bipolar disorder	391

21.3.2	Gut microbiota as a mood state biomarker for bipolar disorder	394
21.3.3	Gut microbiota as a differential diagnosis biomarker for bipolar disorder	394
21.3.4	Gut microbiota as a biomarker of treatment response in bipolar disorder	395
21.4	Main limitations of current research on microbiota-gut-brain axis and bipolar disorder	396
21.5	Conclusions and future directions	396
	References	397
22.	Inflammation, stress and gut-brain axis as therapeutic targets in bipolar disorder	403
	<i>Eleonora D. Vaccariello and Tanya T. Nguyen</i>	
22.1	Introduction	403
22.2	Gastrointestinal dysfunction and inflammation	404
22.3	Gastrointestinal dysfunction in psychiatric disorders	404
22.4	What is the human gut microbiota?	406
22.5	The microbiome-gut-brain axis	410
22.6	Microbiome-gut-brain-axis findings in neuropsychiatric disorders	413
22.6.1	Animal models	413
22.7	Human studies	415
22.8	Bipolar disorder	416
22.9	Treatment	419
22.10	Conclusion and future directions	422
	References	423
23.	Bipolar disorder and plasticity: a key target for new treatment	439
	<i>Sheng-Min Wang and Chi-Un Pae</i>	
23.1	Introduction	439
23.2	Concepts of plasticity and implications in bipolar disorder	439
23.3	Cellular studies	440
23.3.1	Mitochondrial-mediated pathway	440
23.3.2	Neurotrophic factors and associated pathway	441
23.3.3	Glycogen synthase kinase-3 β	442
23.4	Neuroimaging studies	444
23.4.1	Structural magnetic resonance imaging	444
23.4.2	Diffusion tensor imaging	444
23.4.3	Resting-state functional magnetic resonance imaging	445
23.4.4	Neuroinflammation	446
23.5	Drugs development targeting GSK-3 β	447
23.6	Summary	449
	References	451

24. Proteomic biomarkers for bipolar disorder	459
<i>Ather Muneer</i>	
24.1 Introduction	459
24.2 The development of proteomic techniques	460
24.3 Proteome characterization of the peripheral blood	461
24.4 Current status	472
24.5 Differentially abundant proteins	473
24.6 Biological processes and pathways	475
24.7 The future of “OMICS”	475
24.8 Future directions	476
References	477
Further reading	481
 25. Pharmacogenomics in bipolar disorder: towards precision psychiatry and personalized treatment	 483
<i>Brisa S. Fernandes, Alexandre Paim Diaz, João Quevedo, Lokesh Shahani, Marsal Sanches and Jair C. Soares</i>	
25.1 Background	483
25.2 Pharmacogenomics and genetic variation	485
25.3 Pharmacokinetic: drug metabolism	486
25.3.1 CYP2D6	487
25.3.2 CYP2C19	489
25.3.3 CYP2C9	490
25.4 Pharmacogenomics of drugs commonly used in bipolar disorder	490
25.4.1 Valproic acid	490
25.4.2 Lamotrigine and carbamazepine	491
25.4.3 Lithium	491
25.4.4 Antidepressants	492
25.4.5 Atypical antipsychotics	492
25.5 Future directions for the field	492
References	493
 Index	 497